Testing Archives - Page 6 of 26 - Insights
Skip to Content MayoACCESS MayoLINK...
Mayo Clinic Laboratory and Pathology Research Roundup: December 26 - Insights
This week's research roundup feature: Histoplasma and Blastomyces antigen detection assays are commonly used diagnostic tools. However, a high level of cross-reactivity between these antigens prevents definitive pathogen identification by...
Mayo Clinic Laboratory and Pathology Research Roundup: December 12 - Insights
This week's research roundup feature: Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic...
Mayo Clinic Laboratory and pathology research roundup: February 21 - Insights
This week's Research Roundup features: Predicting amyloid PET and tau PET stages with plasma biomarkers.
Mayo Clinic Laboratories, a leading reference laboratory, and Helix, the nation’s leading population genomics and viral surveillance company, today announced a new strategic collaboration that will provide life sciences customers access to...
Novel panel identifies toxins linked to asthma and GI diseases - Insights
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of...
Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.
Antibody against the GABA-A receptor is a biomarker of autoimmune encephalopathy that occurs across the lifespan, and disproportionately affects children. In this test-specific episode of the "Answers From the Lab" podcast, Andrew McKeon,...
Patients with elevated LDL or "bad" cholesterol face even greater risk if their levels of small dense LDL cholesterol are also high. Vlad Vasile, M.D., Ph.D., and Leslie Donato, Ph.D., explain how Mayo Clinic Laboratories' sdLDL-c assay...
Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for...